Orchid Pharma Limited (Orchid Pharma) announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. Chennai-based Orchid Pharma has partnered with Cipla Limited (Cipla) to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.
Allecra Therapeutics (Allecra) and Acino announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June 2024. In addition, the companies have signed a supply agreement under which Allecra will supply the cefepime/enmetazobactam finished product in the above territories.
Orchid Pharma, based in Chennai, has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam.
Orchid Pharma has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market its new chemical entity (NCE), the active pharmaceutical ingredient (API) Enmetazobactam.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Advanz Pharma’s combined antibiotic, cefepime/enmetazobactam, to treat complicated infections.
The United States regulator has signed off on Allecra Therapeutics’ Exblifep (cefepime/enmatazobactam) as a treatment for cUTIs, including the severe kidney condition pyelonephritis, brought on by gram-negative bacteria.
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3
Venatorx and Menarini Enter Agreement for Cefepime-Taniborbactam